Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma

Yohei Ohtake, Kazuki Sudo, Yuki Kojima, Takuji Seo, Hitomi Okuma, Tadaaki Nishikawa, Masaya Uno, Takashi Uehara, Mitsuya Ishikawa, Maki Tanioka, Emi Noguchi, Akihiko Shimomura, Kan Yonemori, Tomoyasu Kato, Yasuhiro Fujiwara, Kenji Tamura

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m2 on days 1-3] and paclitaxel [I35mg/m2 on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.

Original languageEnglish
Pages (from-to)1525-1529
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume46
Issue number10
Publication statusPublished - Oct 2019
Externally publishedYes

Keywords

  • Ifosfamide
  • Paclitaxel
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma'. Together they form a unique fingerprint.

Cite this